Dr. Rapoport on Infections Associated with Anti-CD20 Treatment
Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses infections associated with anti-CD20 treatment.
Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses infections associated with anti-CD20 treatment.
Rapoport says the incidences of infections are higher than what is reported during phase III studies. Even though anti-CD20 agents improve progression-free survival in patients with follicular lymphoma, a meta-analysis of this population shows that the incidence of infection from the drug is higher in those patients who do not receive anti-CD20 agents.
Rapoport says it is important for physicians and nurses to know the signs of infection or progression when dealing with anti-CD20 agents. For example, some patients may present with pulmonary infiltration, which could be a sign of progression or an infection but it could also just be a side effect of the agent.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
